No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 826 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Learning From Being Lost July 14, 2021 A cut above: Making drug discovery more efficient using CRISPR August 16, 2022 Cancer in My Community: Bringing Palliative Care to People With Cancer... February 21, 2023 EMA Recommends Granting a Marketing Authorisation for Duvelisib April 9, 2021 Load more HOT NEWS Cancer in My Community: Obstacles to Caring for People With Cancer... FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... EMA Recommends Extension of Indications for Talazoparib Mom Credits Baby with Saving Her Life After She was Diagnosed...
